Latest News

Date Title Topic
21 Dec 2016 FDA Grants Accelerated Approval to Rucaparib for Previously Treated, BRCA Mutated Advanced Ovarian Cancer Personalised medicine - Gynaecologic malignancies - Anticancer agents & Biologic therapy
20 Dec 2016 EMA Recommends Granting a Marketing Authorisation for Biosimilar Rituximab Haematologic malignancies - Anticancer agents & Biologic therapy
19 Dec 2016 ESMO Patient Guides in Liver and Bladder Cancers
19 Dec 2016 EMA Recommends to Extend Indications for Pembrolizumab Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
Webcasts
18 Dec 2016 ESMO Asia 2016 Press Release: Immunotherapy with Pembrolizumab Deemed Cost-Effective for Advanced Melanoma Patients in Hong Kong Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
18 Dec 2016 ESMO Asia 2016 Press Release: Routine Blood Test Predicts How Long Cancer Patients Will Survive Palliative and supportive care
18 Dec 2016 ESMO Asia 2016 Press Release: Cancer Costs Leaving Patients in Debt Bioethics, legal and economic issues
18 Dec 2016 ESMO Asia 2016 Press Release: Depressed Patients Are Less Responsive to Chemotherapy Anticancer agents & Biologic therapy
18 Dec 2016 ESMO Asia 2016 Press Release: Anxiety and Depression a Major Issue for Cancer Survivors
18 Dec 2016 ESMO Asia 2016 Press Release: Ribociclib Improves Progression-free Survival in Asian Women with Advanced Breast Cancer Breast cancer
Photo Reportage
17 Dec 2016 ESMO Asia 2016 Press Release: First Data on Rare Sarcomas in Asian Patients Presented at ESMO Asia in Singapore Sarcomas
16 Dec 2016 EMA Recommends Granting a Conditional Marketing Authorisation for Alectinib for the Treatment of ALK-Positive Advanced NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
15 Dec 2016 ESMO Asia 2016 Media Alert: ESMO Asia Congress to Return to Singapore for the 2nd Time